The FDA approved Amgen and Wyeth Pharmaceuticals drug, Enbrel (etanercept), to inhibit the progression of structural damage in patients with active psoriatic arthritis and reduce its signs and symptoms.
Xkin Suture Device Acts as Effective Wound Closure Method, Improves Scar Outcomes
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised
Managing Food Allergies with Dupilumab in Pediatric Dermatology